A Double-blind, Randomized, Multicenter Phase 3 Study of Palonosetron Vs Granisetron Combined with Dexamethasone and Fosaprepitant to Prevent Chemotherapy-induced Nausea and Vomiting in Patients with Breast Cancer Receiving Anthracycline And...

Overview

Journal Cancer Med

Specialty Oncology

Date 2020 Mar 14

PMID 32168551

Citations 14

Authors

Koji Matsumoto

Masato Takahashi

Kazuhiko Sato

Akihiko Osaki

Toshimi Takano

Yoichi Naito

Kazuo Matsuura

Kenjiro Aogi

Kimiko Fujiwara

Kenji Tamura

Motoi Baba

Shinya Tokunaga

Gen Hirano

Shigeru Imoto

Chieko Miyazaki

Kazuhiro Yanagihara

Chiyo K Imamura

Yasutaka Chiba

Toshiaki Saeki

Affiliations

Soon will be listed here.

Abstract

Purpose: To investigate whether palonosetron is better than granisetron in preventing chemotherapy-induced nausea and vomiting (CINV) in a three-drug combination with dexamethasone and fosaprepitant (Fos) in patients with breast cancer who are placed on anthracycline and cyclophosphamide (AC-based regimen).

Patients And Methods: Chemo-naive women with primary breast cancer were randomly administered either palonosetron 0.75 mg (day 1) or granisetron 1 mg (day 1) combined with dexamethasone (12 mg at day 1, 8 mg at day 2 and day 3) and Fos 150 mg (day 1) before receiving AC-based regimen in a double-blind study. The primary endpoint was the complete response (CR) rate of emesis in cycle 1 in the delayed phase. This was defined as neither vomiting nor rescue drug usage for emesis at >24-120 hours after chemotherapy. Secondary endpoints were the CR in the acute/overall phase (0-24/0-120 hours, respectively, after chemotherapy), no nausea and vomiting, Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE), and safety.

Results: From December 2012 to October 2014, 326 patients were treated and evaluated (164/162 evaluable patients in granisetron/palonosetron arm, respectively). The CR during the delayed phase was 60.4% in the granisetron regimen and 62.3% in the palonosetron regimen. The CR during acute phase (73.2% vs 75.9%, respectively) and the CR during overall phase (54.9% in both regimens) were very identical. A significantly higher number of patients in the palonosetron arm were free from nausea during the delayed phase (28% vs 40.1%; P = .029). Adverse events were also identical, although infusion site reactions (ISR) were higher (20.3%-23.3%) than preceding studies in both regimens.

Conclusion: In combination with dexamethasone and Fos, this study suggests that palonosetron is not better than granisetron in chemo-naive patients with primary breast cancer receiving AC-based regimen. Administration of Fos in peripheral veins after AC-based regimen increased ISR.

Citing Articles

Comparison of olanzapine 2.5 mg and 5 mg in the prevention of chemotherapy-induced nausea and vomiting: a Japanese nationwide database study.

Suzuki-Chiba H, Konishi T, Aso S, Makito K, Matsui H, Jo T Int J Clin Oncol. 2024; 29(11):1762-1773.

PMID: 39154312 PMC: 11511693. DOI: 10.1007/s10147-024-02603-2.

Dexamethasone-sparing strategies in anthracycline and cyclophosphamide-based chemotherapy with a focus on 5-HT3 receptor antagonists: a network meta-analysis.

Watanabe D, Iihara H, Kobayashi R, Fujii H, Mori R, Kumada K Front Oncol. 2024; 14:1414037.

PMID: 39132500 PMC: 11310115. DOI: 10.3389/fonc.2024.1414037.

2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting.

Herrstedt J, Clark-Snow R, Ruhlmann C, Molassiotis A, Olver I, Rapoport B ESMO Open. 2024; 9(2):102195.

PMID: 38458657 PMC: 10937211. DOI: 10.1016/j.esmoop.2023.102195.

2023 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high-emetic-risk antineoplastic agents.

Herrstedt J, Celio L, Hesketh P, Zhang L, Navari R, Chan A Support Care Cancer. 2023; 32(1):47.

PMID: 38127246 PMC: 10739516. DOI: 10.1007/s00520-023-08221-4.

Influence of menopause on chemotherapy-induced nausea and vomiting in highly emetogenic chemotherapy for breast cancer: A retrospective observational study.

Yokokawa T, Suzuki K, Tsuji D, Hosonaga M, Kobayashi K, Kawakami K Cancer Med. 2023; 12(18):18745-18754.

PMID: 37676079 PMC: 10557896. DOI: 10.1002/cam4.6494.

References

Leal A, Kadakia K, Looker S, Hilger C, Sorgatz K, Anderson K . Fosaprepitant-induced phlebitis: a focus on patients receiving doxorubicin/cyclophosphamide therapy. Support Care Cancer. 2014; 22(5):1313-7. PMC: 3969765. DOI: 10.1007/s00520-013-2089-8. View

Basch E, Prestrud A, Hesketh P, Kris M, Feyer P, Somerfield M . Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2011; 29(31):4189-98. PMC: 4876353. DOI: 10.1200/JCO.2010.34.4614. View

Warr D, Hesketh P, Gralla R, Muss H, Herrstedt J, Eisenberg P . Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy. J Clin Oncol. 2005; 23(12):2822-30. DOI: 10.1200/JCO.2005.09.050. View

Maemondo M, Masuda N, Sekine I, Kubota K, Segawa Y, Shibuya M . A phase II study of palonosetron combined with dexamethasone to prevent nausea and vomiting induced by highly emetogenic chemotherapy. Ann Oncol. 2009; 20(11):1860-6. DOI: 10.1093/annonc/mdp195. View

Tamura K, Aiba K, Saeki T, Nakanishi Y, Kamura T, Baba H . Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan. Int J Clin Oncol. 2015; 20(5):855-65. DOI: 10.1007/s10147-015-0786-7. View

Hesketh P, Bohlke K, Lyman G, Basch E, Chesney M, Clark-Snow R . Antiemetics: American Society of Clinical Oncology Focused Guideline Update. J Clin Oncol. 2015; 34(4):381-6. DOI: 10.1200/JCO.2015.64.3635. View

Matsumoto K, Takahashi M, Sato K, Osaki A, Takano T, Naito Y . A double-blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy-induced nausea and vomiting in patients with breast cancer receiving anthracycline and.... Cancer Med. 2020; 9(10):3319-3327. PMC: 7221309. DOI: 10.1002/cam4.2979. View

Takahashi T, Hoshi E, Takagi M, Katsumata N, Kawahara M, Eguchi K . Multicenter, phase II, placebo-controlled, double-blind, randomized study of aprepitant in Japanese patients receiving high-dose cisplatin. Cancer Sci. 2010; 101(11):2455-61. PMC: 11159452. DOI: 10.1111/j.1349-7006.2010.01689.x. View

Segawa Y, Aogi K, Inoue K, Sano M, Sekine I, Tokuda Y . A phase II dose-ranging study of palonosetron in Japanese patients receiving moderately emetogenic chemotherapy, including anthracycline and cyclophosphamide-based chemotherapy. Ann Oncol. 2009; 20(11):1874-80. DOI: 10.1093/annonc/mdp243. View

10.

Eisenberg P, Figueroa-Vadillo J, Zamora R, Charu V, Hajdenberg J, Cartmell A . Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer. 2003; 98(11):2473-82. DOI: 10.1002/cncr.11817. View

11.

Navari R, Qin R, Ruddy K, Liu H, Powell S, Bajaj M . Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. N Engl J Med. 2016; 375(2):134-42. PMC: 5344450. DOI: 10.1056/NEJMoa1515725. View

12.

Ito Y, Tsuda T, Minatogawa H, Kano S, Sakamaki K, Ando M . Placebo-Controlled, Double-Blinded Phase III Study Comparing Dexamethasone on Day 1 With Dexamethasone on Days 1 to 3 With Combined Neurokinin-1 Receptor Antagonist and Palonosetron in High-Emetogenic Chemotherapy. J Clin Oncol. 2018; 36(10):1000-1006. DOI: 10.1200/JCO.2017.74.4375. View

13.

Hesketh P, Warr D, Street J, Carides A . Differential time course of action of 5-HT3 and NK1 receptor antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC). Support Care Cancer. 2010; 19(9):1297-302. DOI: 10.1007/s00520-010-0944-4. View

14.

Grunberg S, Chua D, Maru A, Dinis J, DeVandry S, Boice J . Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE. J Clin Oncol. 2011; 29(11):1495-501. DOI: 10.1200/JCO.2010.31.7859. View

15.

Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla R, Bruera E . 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol. 2016; 27(suppl 5):v119-v133. DOI: 10.1093/annonc/mdw270. View

16.

Hesketh P, Kris M, Basch E, Bohlke K, Barbour S, Clark-Snow R . Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2017; 35(28):3240-3261. DOI: 10.1200/JCO.2017.74.4789. View

17.

Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H . Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol. 2009; 10(2):115-24. DOI: 10.1016/S1470-2045(08)70313-9. View

18.

Aapro M, Grunberg S, Manikhas G, Olivares G, Suarez T, Tjulandin S . A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann Oncol. 2006; 17(9):1441-9. DOI: 10.1093/annonc/mdl137. View

19.

Gralla R, Lichinitser M, van der Vegt S, Sleeboom H, Mezger J, Peschel C . Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol. 2003; 14(10):1570-7. DOI: 10.1093/annonc/mdg417. View

20.

Suzuki K, Yamanaka T, Hashimoto H, Shimada Y, Arata K, Matsui R . Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study. Ann Oncol. 2016; 27(8):1601-6. DOI: 10.1093/annonc/mdw220. View